M. Toth

发表

CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer’s disease

C. Tatsuoka, A. Lerner, A. Pieper, 2022, Alzheimer's Research & Therapy.

Malignancies after renal transplantation during 33 years at a single center

É. Toronyi, E. Dinya, J. Járay, 2007, Pathology & Oncology Research.

Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas.

J. Járay, G. Barna, L. Kopper, 2007, Leukemia research.

Gas chromatography nitrogen phosphorous detection (GC-NPD) assay of tofisopam in human plasma for pharmacokinetic evaluation.

I. Klebovich, S. Drabant, B. Varga, 2006, Journal of pharmaceutical and biomedical analysis.

Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation.

Jorge M Serrador, J. Serrador, J. Mullington, 2009, Progress in cardiovascular diseases.

Increased stress response and beta-phenylethylamine in MAOB-deficient mice.

J. Shih, T. Kumazawa, J. Adams, 1997, Nature genetics.

[Effect of tofisopam on CYP3A4 enzyme activity on human recombinant 3A4 supersome].

I. Klebovich, S. Drabant, A. Egyed, 2005, Acta pharmaceutica Hungarica.

Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam

I. Klebovich, S. Drabant, A. Bereczki, 2006, European Journal of Clinical Pharmacology.

Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam

I. Klebovich, S. Drabant, M. Tóth, 2007, European Journal of Clinical Pharmacology.